Publication Name	World Journal of Cardiology
Manuscript ID	66137
Country	Croatia

Received	2021-03-23 20:21
Peer-Review Started	2021-03-23 20:23
To Make the First Decision
Return for Revision	2021-07-30 04:59
Revised	2021-08-06 08:43
Second Decision	2021-10-22 06:45
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-10-25 02:08
Articles in Press	2021-10-25 02:08
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-11-23 12:34
Publish the Manuscript Online	2021-11-25 06:50

ISSN	1949-8462 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Opinion Review
Article Title	Safety and efficacy of dual antiplatelet therapy after percutaneous coronary interventions in patients with end-stage liver disease
Manuscript Source	Invited Manuscript
All Author List	Zvonimir Ostojic, Ana Ostojic, Josko Bulum and Anna Mrzljak
Funding Agency and Grant Number
Corresponding Author	Ana Ostojic, MD, PhD, Senior Postdoctoral Fellow, Department of Gastroenterology and Hepatology, University Hospital Center, Kispaticeva 12, Zagreb 10000, Croatia. ostojicana.zg@gmail.com
Key Words	End-stage liver disease; Cirrhosis; Liver transplantation; Coronary artery disease; Percutaneous coronary intervention; Antiplatelet therapy
Core Tip	Dual antiplatelet therapy (DAPT) is necessary after a percutaneous coronary intervention (PCI). However, it could result in severe consequences in patients with liver cirrhosis. Based on novel findings, liver cirrhosis does not necessarily lead to a significant increase in bleeding complications. Patients with cirrhosis who have the highest bleeding risk are those with severe thrombocytopenia and elevated portal pressure. Despite the lack of solid evidence for DAPT in patients with cirrhosis, trials investigating one month of DAPT duration after PCI can be implemented in cirrhotic patients. Before PCI, functional assessment of coronary artery disease severity should be performed to avoid unnecessary interventions.
Publish Date	2021-11-25 06:50
Citation	Ostojic Z, Ostojic A, Bulum J, Mrzljak A. Safety and efficacy of dual antiplatelet therapy after percutaneous coronary interventions in patients with end-stage liver disease. World J Cardiol 2021; 13(11): 599-607
URL	https://www.wjgnet.com/1949-8462/full/v13/i11/599.htm
DOI	https://dx.doi.org/10.4330/wjc.v13.i11.599

Full Article (PDF)	WJC-13-599.pdf
Full Article (Word)	WJC-13-599.docx
Manuscript File	66137_Auto_Edited.docx
Answering Reviewers	66137-Answering reviewers.pdf
Audio Core Tip	66137-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	66137-Conflict-of-interest statement.pdf
Copyright License Agreement	66137-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	66137-Language certificate.pdf
Peer-review Report	66137-Peer-review(s).pdf
Scientific Editor Work List	66137-Scientific editor work list.pdf